They just don't get it over there. The combo patent would extend the patent protection of the molecule used in the combo in the AD designation. Therefore you can sell the monotherapy knowing that the "unused" combo patent covers the molecule for AD sold by itself or not. Companies have many tricks to extend patents.
Have you read the Anavex initiated interview summary on the USPTO public PAIR database from 12-19 about the combo patent?
News 
Market Data 
Discover 
